Zymeworks (ZYME) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 8, 2022 4:22 PM ESTAnnounced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Early Research and Development day highlighting progress in development of product pipeline and potential applications of proprietary next-generation technology platforms Completed plan to become a Delaware corporation, providing opportunities for enhanced long-term value for securityholders, simplified commercialization efforts and monetization opportunities for product candidates, and greater comparability to peers Reported encouraging preliminary Phase 1 trial results for zanidatamab zovodotin at ESMO Congress, with zanidatamab... More
